



Balfour Capital Group Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is a global leader in serving science, offering a wide range of products and services including analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotechnology companies. Their mission is to enable customers to make the world healthier, cleaner, and safer.

1. Top 5 Competitors

Thermo Fisher's primary competitors include:

1. Danaher Corporation
2. Agilent Technologies Inc.
3. Becton, Dickinson and Company (BD)
4. Illumina Inc.
5. Bruker Corporation

These companies compete in various segments such as life sciences, diagnostics, and analytical instruments.

2. Largest Institutional Shareholders

As of the latest filings, the largest institutional shareholders of Thermo Fisher Scientific are:

- Vanguard Group Inc. – 8.813% ownership
- BlackRock Inc. – 5.544% ownership
- State Street Corporation – 4.36% ownership

These institutions collectively hold a significant portion of the company's shares.

3. Management Team

Thermo Fisher's executive leadership includes:

- Marc N. Casper – Chairman, President, and CEO
- Michel Lagarde – Executive Vice President and Chief Operating Officer
- Stephen Williamson – Senior Vice President and Chief Financial Officer
- Karen E. Nelson – Chief Scientific Officer
- Alan Sachs – Chief Medical Officer

This team oversees the company's strategic direction and operations.



Balfour Capital Group Thermo Fisher Scientific Inc.

4. Revenue

For the fiscal year 2024, Thermo Fisher Scientific reported: Reuters

- Annual Revenue: \$42.879 billion
- Year-over-Year Growth: 0.05% increase from 2023

The company's revenue has remained relatively stable, reflecting its diversified portfolio and global reach.

5. Institutions with Buy Recommendations:

Several financial institutions and analysts have issued buy recommendations for Thermo Fisher Scientific, including:

- Wells Fargo & Company – Maintained a “Buy” rating with a price target of \$680
- RBC Capital – Maintained a “Buy” rating
- Morningstar – Highlighted the stock as an attractive buy due to its robust cash flow and wide economic

6. Analyst Sentiment Summary

Analyst sentiment towards Thermo Fisher Scientific is predominantly positive:

- Consensus Rating: Moderate Buy
- Average 12-Month Price Target: \$607.43
- Strong Buy Ratings: 17 analysts
- Hold Ratings: 4 analysts

This reflects confidence in the company's long-term growth prospects.

7. Insider Buying and Selling (Last 24 Months)

Over the past two years, insider trading activity includes:

- Total Shares Sold by Insiders: 227,011 shares
- Total Value of Shares Sold: Approximately \$125.5 million

Notable transactions:

- Michael Boxer (Director) sold shares worth over \$2 million in March 2025
- Lisa Britt (Executive) sold shares worth approximately \$2.2 million in July 2024

These transactions are part of regular insider trading activities and may not necessarily indicate changes in company outlook.